JP2017508789A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508789A5 JP2017508789A5 JP2016570944A JP2016570944A JP2017508789A5 JP 2017508789 A5 JP2017508789 A5 JP 2017508789A5 JP 2016570944 A JP2016570944 A JP 2016570944A JP 2016570944 A JP2016570944 A JP 2016570944A JP 2017508789 A5 JP2017508789 A5 JP 2017508789A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- independently selected
- hydroxyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 14
- 150000002367 halogens Chemical class 0.000 claims 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- -1 nitro, cyano, amino Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 101100240527 Caenorhabditis elegans nhr-22 gene Proteins 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000004011 3 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 1
- 208000016323 C3 glomerulonephritis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 102000003706 Complement factor D Human genes 0.000 claims 1
- 108090000059 Complement factor D Proteins 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- IRNZUPKJFZUCCS-QRQCRPRQSA-N C=[F][C@H](C[C@H]1C(Nc(cccc2-c(cccc3)c3Cl)c2F)=O)CN1C(C[n]1c([s]cc2)c2c(C(N)=O)c1)=O Chemical compound C=[F][C@H](C[C@H]1C(Nc(cccc2-c(cccc3)c3Cl)c2F)=O)CN1C(C[n]1c([s]cc2)c2c(C(N)=O)c1)=O IRNZUPKJFZUCCS-QRQCRPRQSA-N 0.000 description 1
- TVFJDHJADARRAG-VLIAUNLRSA-N Cc1cc([n](CC(N(C[C@@H](C2)F)[C@@H]2C(Nc(cccc2-c(cccc3)c3Cl)c2F)=O)=O)nc2C(N)=O)c2[s]1 Chemical compound Cc1cc([n](CC(N(C[C@@H](C2)F)[C@@H]2C(Nc(cccc2-c(cccc3)c3Cl)c2F)=O)=O)nc2C(N)=O)c2[s]1 TVFJDHJADARRAG-VLIAUNLRSA-N 0.000 description 1
- UKAWMRYCPWTAFH-OCCSQVGLSA-N Cc1cc([n](CC(N(C[C@@H](C2)F)[C@@H]2C(Nc2nc(C)ccc2)=O)=O)nc2C(N)=O)c2[s]1 Chemical compound Cc1cc([n](CC(N(C[C@@H](C2)F)[C@@H]2C(Nc2nc(C)ccc2)=O)=O)nc2C(N)=O)c2[s]1 UKAWMRYCPWTAFH-OCCSQVGLSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461944189P | 2014-02-25 | 2014-02-25 | |
| US61/944,189 | 2014-02-25 | ||
| US201462022916P | 2014-07-10 | 2014-07-10 | |
| US62/022,916 | 2014-07-10 | ||
| US201462046783P | 2014-09-05 | 2014-09-05 | |
| US62/046,783 | 2014-09-05 | ||
| PCT/US2015/017609 WO2015130854A1 (en) | 2014-02-25 | 2015-02-25 | Compounds for treatment of complement mediated disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508789A JP2017508789A (ja) | 2017-03-30 |
| JP2017508789A5 true JP2017508789A5 (enExample) | 2018-04-05 |
| JP6537532B2 JP6537532B2 (ja) | 2019-07-03 |
Family
ID=53881572
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570944A Active JP6537532B2 (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のための化合物 |
| JP2016570938A Pending JP2017506672A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介性疾患の治療用アミノ化合物 |
| JP2016570940A Active JP6400738B2 (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2016570941A Pending JP2017508788A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのエーテル化合物 |
| JP2016570937A Pending JP2017506269A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのアミド化合物 |
| JP2016570942A Pending JP2017507184A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのホスホネート化合物 |
| JP2018164274A Active JP6688352B2 (ja) | 2014-02-25 | 2018-09-03 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2020060825A Active JP6948426B2 (ja) | 2014-02-25 | 2020-03-30 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2021150181A Active JP7374967B2 (ja) | 2014-02-25 | 2021-09-15 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016570938A Pending JP2017506672A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介性疾患の治療用アミノ化合物 |
| JP2016570940A Active JP6400738B2 (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2016570941A Pending JP2017508788A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのエーテル化合物 |
| JP2016570937A Pending JP2017506269A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのアミド化合物 |
| JP2016570942A Pending JP2017507184A (ja) | 2014-02-25 | 2015-02-25 | 補体媒介障害の治療のためのホスホネート化合物 |
| JP2018164274A Active JP6688352B2 (ja) | 2014-02-25 | 2018-09-03 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2020060825A Active JP6948426B2 (ja) | 2014-02-25 | 2020-03-30 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
| JP2021150181A Active JP7374967B2 (ja) | 2014-02-25 | 2021-09-15 | 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (33) | US9732103B2 (enExample) |
| EP (10) | EP3110804A4 (enExample) |
| JP (9) | JP6537532B2 (enExample) |
| KR (7) | KR102383714B1 (enExample) |
| CN (8) | CN106456605A (enExample) |
| AP (5) | AP2016009435A0 (enExample) |
| AU (7) | AU2015223084B2 (enExample) |
| BR (1) | BR112016019526B1 (enExample) |
| CA (6) | CA2940777A1 (enExample) |
| CY (1) | CY1122550T1 (enExample) |
| DK (1) | DK3110418T3 (enExample) |
| EA (5) | EA201691727A1 (enExample) |
| ES (2) | ES2933956T3 (enExample) |
| FI (1) | FIC20240030I1 (enExample) |
| FR (1) | FR24C1034I2 (enExample) |
| HR (2) | HRP20200182T1 (enExample) |
| HU (2) | HUE047295T2 (enExample) |
| IL (8) | IL301427B2 (enExample) |
| LT (3) | LT3110418T (enExample) |
| MX (6) | MX2016011036A (enExample) |
| NL (1) | NL301286I2 (enExample) |
| PL (1) | PL3110418T3 (enExample) |
| PT (1) | PT3110418T (enExample) |
| RS (2) | RS59854B1 (enExample) |
| RU (3) | RU2016137524A (enExample) |
| SA (1) | SA516371744B1 (enExample) |
| SI (1) | SI3110418T1 (enExample) |
| SM (1) | SMT202000046T1 (enExample) |
| WO (8) | WO2015130806A1 (enExample) |
| ZA (2) | ZA201605829B (enExample) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201691727A1 (ru) | 2014-02-25 | 2017-01-30 | Ачиллион Фармасьютикалс, Инк. | Фосфонатные соединения для лечения опосредованных комплементом нарушений |
| CA2977981C (en) | 2015-02-27 | 2023-03-21 | The Johns Hopkins University | Assay to diagnose and treat disorders of the alternative pathway of complement activation |
| AR106018A1 (es) * | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| WO2017035361A1 (en) * | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017098328A2 (en) * | 2015-12-11 | 2017-06-15 | Lifesci Phamaceuticals, Inc. | Therapeutic inhibitory compounds |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| TWI850624B (zh) | 2015-12-22 | 2024-08-01 | 美商英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CA3011819A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| TWI854164B (zh) * | 2016-02-01 | 2024-09-01 | 美商百歐克斯製藥公司 | 苯并吡唑化合物及其類似物 |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| DK3472167T3 (da) | 2016-06-20 | 2022-09-05 | Incyte Corp | Heterocykliske forbindelser som immunomodulatorer |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20190292155A1 (en) * | 2016-07-15 | 2019-09-26 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| DE102016114392A1 (de) * | 2016-08-03 | 2018-02-08 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Verbindung zur Behandlung einer mit einer Desregulierung des alternativen Komplementweges assoziierten Erkrankung |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| TWI771319B (zh) | 2016-09-09 | 2022-07-21 | 美商英塞特公司 | 吡唑并吡啶化合物及其用途 |
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| IL295660A (en) | 2016-12-22 | 2022-10-01 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2929193T3 (es) | 2016-12-22 | 2022-11-25 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1 |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| CA3054167A1 (en) * | 2017-02-27 | 2018-08-30 | Regeneron Pharmaceuticals, Inc. | Humanized model of kidney and liver disorders |
| AU2018227849B2 (en) * | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| WO2018160892A1 (en) * | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| WO2018229543A2 (en) * | 2017-06-14 | 2018-12-20 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CN111163767A (zh) | 2017-08-02 | 2020-05-15 | 艾其林医药公司 | 治疗阵发性睡眠性血红蛋白尿症的治疗方案 |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| KR101969521B1 (ko) * | 2017-10-26 | 2019-08-13 | 에스케이텔레콤 주식회사 | 사물인터넷용 단말과 모바일 단말의 접속을 관리하는 방법 및 이러한 방법을 수행하는 기지국 |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10800761B2 (en) | 2018-02-20 | 2020-10-13 | Incyte Corporation | Carboxamide compounds and uses thereof |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| RS64055B1 (sr) | 2018-03-30 | 2023-04-28 | Incyte Corp | Heterociklična jedinjenja kao imunomodulatori |
| TWI873092B (zh) | 2018-04-06 | 2025-02-21 | 美商百歐克斯製藥公司 | 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑 |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| EP4219492B1 (en) | 2018-05-11 | 2024-11-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| KR20210016545A (ko) | 2018-05-29 | 2021-02-16 | 오메로스 코포레이션 | Masp-2 억제제 및 사용 방법 |
| WO2019236884A1 (en) * | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| JP7538113B2 (ja) * | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| EP3847174A4 (en) * | 2018-09-06 | 2022-06-15 | Achillion Pharmaceuticals, Inc. | MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS |
| JP2022502500A (ja) * | 2018-09-25 | 2022-01-11 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体因子ｄ阻害剤の形態 |
| MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
| EP3873464B1 (en) * | 2018-11-01 | 2025-07-30 | Merck Sharp & Dohme LLC | Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors |
| WO2020112581A1 (en) * | 2018-11-28 | 2020-06-04 | Merck Sharp & Dohme Corp. | Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| JP7471300B2 (ja) | 2018-12-17 | 2024-04-19 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体介在性疾患を治療するための的を絞った投与 |
| EP3941462A4 (en) | 2019-03-22 | 2023-04-05 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES |
| CA3148119A1 (en) * | 2019-07-31 | 2021-02-04 | Biocryst Pharmaceuticals, Inc. | Dosing regimens for oral complement factor d inhibitors |
| PE20221419A1 (es) | 2019-08-06 | 2022-09-20 | Incyte Corp | Formas solidas de un inhibidor de hpk1 |
| JP7665593B2 (ja) | 2019-08-09 | 2025-04-21 | インサイト・コーポレイション | Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩 |
| EP4037773A1 (en) | 2019-09-30 | 2022-08-10 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| WO2021113682A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| EP4069676A1 (en) * | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| US20210335448A1 (en) * | 2020-04-27 | 2021-10-28 | Advaita Corporation | Methods of identifying treatments using differentially expressed genes |
| US11759452B2 (en) | 2020-05-08 | 2023-09-19 | Psilera Inc. | Compositions of matter and pharmaceutical compositions |
| CN113777302A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液补体因子d及其多肽片段在烧伤中的应用 |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| JP7787164B2 (ja) * | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| EP4240739A1 (en) | 2020-11-06 | 2023-09-13 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
| US12378194B2 (en) | 2021-05-25 | 2025-08-05 | Atai Therapeutics, Inc. | N, n-dimethyltryptamine salts and crystalline salt forms |
| WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
| CA3233486A1 (en) * | 2021-09-30 | 2023-04-06 | Jun LOU | Compound as inhibitor of complement factor d, and pharmaceutical composition and use thereof |
| WO2023158772A1 (en) | 2022-02-21 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Solid state forms of danicopan and process thereof |
| WO2024008121A1 (zh) * | 2022-07-06 | 2024-01-11 | 南京明德新药研发有限公司 | 二氟取代的氮杂双环化合物及其应用 |
| CA3201039A1 (en) * | 2023-03-13 | 2025-03-12 | Alexion Pharmaceuticals, Inc. | Formulations of danicopan and methods of use thereof |
| WO2025019800A1 (en) * | 2023-07-19 | 2025-01-23 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| WO2026014456A1 (ja) * | 2024-07-10 | 2026-01-15 | 株式会社アークメディスン | 化合物、補体ｄ因子阻害剤、及び医薬組成物 |
| WO2026037430A1 (zh) * | 2024-08-16 | 2026-02-19 | 武汉朗来科技发展有限公司 | 一种补体因子d抑制剂的制备方法、其中间体及中间体的制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6653340B1 (en) | 1997-06-03 | 2003-11-25 | Biocryst Pharmaceuticals, Inc. | Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| TR200003598T2 (tr) | 1998-03-26 | 2001-06-21 | Japan Tobacco Inc. | Amid türevleri ve nosiseptin antagonistleri |
| DE69910045T2 (de) | 1998-09-09 | 2004-04-22 | Metabasis Therapeutics Inc., San Diego | Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren |
| AU6868900A (en) | 1999-09-03 | 2001-04-10 | Ajinomoto Co., Inc. | Novel processes for preparing oxazepine derivatives |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| JP2006504651A (ja) | 2002-07-16 | 2006-02-09 | アミュラ テラピューティクス リミテッド | 生物活性化合物 |
| AU2003302084A1 (en) | 2002-11-15 | 2004-06-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
| AU2003902946A0 (en) | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| EP1727811B1 (en) | 2004-03-24 | 2014-11-12 | Shire Orphan Therapies GmbH | New compounds for the inhibition of angiogenesis and use of thereof |
| US7417063B2 (en) | 2004-04-13 | 2008-08-26 | Bristol-Myers Squibb Company | Bicyclic heterocycles useful as serine protease inhibitors |
| WO2006012373A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| US7626039B2 (en) * | 2005-12-14 | 2009-12-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors |
| JPWO2008047831A1 (ja) | 2006-10-17 | 2010-02-25 | 協和発酵キリン株式会社 | Ｊａｋ阻害剤 |
| CA2674865A1 (en) | 2007-01-15 | 2008-07-24 | Santen Pharmaceutical Co., Ltd. | Indole derivative having i.kappa.b kinase .beta. inhibitory activity |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| CA2777013A1 (en) | 2009-10-16 | 2011-04-21 | Mochida Pharmaceutical Co., Ltd. | Marker associated with non-alcoholic steatohepatitis |
| CA2794808C (en) | 2010-04-16 | 2019-08-20 | Ac Immune S.A. | Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| WO2012093101A1 (en) | 2011-01-04 | 2012-07-12 | Novartis Ag | Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd) |
| CN103929961A (zh) | 2011-06-20 | 2014-07-16 | 美国阿尔茨海默病研究所公司 | 化合物及其治疗应用 |
| US10039802B2 (en) | 2011-06-22 | 2018-08-07 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| KR20150006869A (ko) | 2012-05-03 | 2015-01-19 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| US9056874B2 (en) * | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| CA2876993A1 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| EP2867226B1 (en) | 2012-06-28 | 2018-11-14 | Novartis AG | Complement pathway modulators and uses thereof |
| JP6154897B2 (ja) | 2012-06-28 | 2017-06-28 | ノバルティス アーゲー | ピロリジン誘導体、および補体経路調節因子としてのその使用 |
| ES2647124T3 (es) | 2012-06-28 | 2017-12-19 | Novartis Ag | Derivados de pirrolidina y su uso como moduladores de la ruta del complemento |
| WO2014002053A1 (en) | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| US9487483B2 (en) * | 2012-06-28 | 2016-11-08 | Novartis Ag | Complement pathway modulators and uses thereof |
| WO2014002059A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide |
| WO2014005150A1 (en) | 2012-06-29 | 2014-01-03 | Novartis Ag | Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof |
| ITMI20121156A1 (it) * | 2012-06-29 | 2013-12-30 | Consiglio Nazionale Ricerche | Metodo di elaborazione di immagini di tomografia a coerenza ottica |
| JP6238980B2 (ja) | 2012-07-12 | 2017-11-29 | ノバルティス アーゲー | 補体経路モジュレーターおよびその使用 |
| JP6113285B2 (ja) | 2012-09-10 | 2017-04-12 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療及び予防用の６−アミノ酸ヘテロアリールジヒドロピリミジン |
| US9773428B2 (en) | 2012-12-11 | 2017-09-26 | Fluidity Software, Inc. | Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems |
| HK1218300A1 (zh) | 2013-01-23 | 2017-02-10 | Musc Foundation For Research Development | 基於天然抗體的靶向結構體及其應用 |
| JP2016169161A (ja) | 2013-07-19 | 2016-09-23 | 大日本住友製薬株式会社 | 新規イミダゾピリジン化合物 |
| EA201691727A1 (ru) | 2014-02-25 | 2017-01-30 | Ачиллион Фармасьютикалс, Инк. | Фосфонатные соединения для лечения опосредованных комплементом нарушений |
| AR105808A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos de amida para el tratamiento de trastornos médicos |
| WO2017035348A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of medical disorders |
| WO2017035361A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for the treatment of medical disorders |
| US10000516B2 (en) | 2015-08-26 | 2018-06-19 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| WO2017035413A2 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| ES2908479T3 (es) | 2015-08-26 | 2022-04-29 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos inmunitarios e inflamatorios |
| WO2017035418A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Disubstituted compounds for treatment of immune and inflammatory disorders |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| US10385097B2 (en) | 2015-08-26 | 2019-08-20 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of medical disorders |
| WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| WO2017035351A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of medical disorders |
| WO2017035411A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Ether compounds for treatment of immune and inflammatory disorders |
| WO2017035415A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Alkyne compounds for treatment of immune and inflammatory disorders |
| WO2017035352A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Carbamate, ester, and ketone compounds for treatment of medical disorders |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035417A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of immune and inflammatory disorders |
| WO2017098328A2 (en) | 2015-12-11 | 2017-06-15 | Lifesci Phamaceuticals, Inc. | Therapeutic inhibitory compounds |
| CA3011819A1 (en) | 2016-01-20 | 2017-07-27 | Vitrisa Therapeutics, Inc. | Compositions and methods for inhibiting factor d |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| AU2018227849B2 (en) | 2017-03-01 | 2022-04-28 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
| WO2018160892A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
-
2015
- 2015-02-25 EA EA201691727A patent/EA201691727A1/ru unknown
- 2015-02-25 EP EP15755090.6A patent/EP3110804A4/en not_active Withdrawn
- 2015-02-25 AP AP2016009435A patent/AP2016009435A0/en unknown
- 2015-02-25 AU AU2015223084A patent/AU2015223084B2/en not_active Ceased
- 2015-02-25 MX MX2016011036A patent/MX2016011036A/es unknown
- 2015-02-25 ES ES19206925T patent/ES2933956T3/es active Active
- 2015-02-25 DK DK15755617.6T patent/DK3110418T3/da active
- 2015-02-25 HR HRP20200182TT patent/HRP20200182T1/hr unknown
- 2015-02-25 AU AU2015223068A patent/AU2015223068B2/en active Active
- 2015-02-25 CA CA2940777A patent/CA2940777A1/en active Pending
- 2015-02-25 WO PCT/US2015/017554 patent/WO2015130806A1/en not_active Ceased
- 2015-02-25 KR KR1020167026096A patent/KR102383714B1/ko active Active
- 2015-02-25 US US14/631,440 patent/US9732103B2/en active Active
- 2015-02-25 RU RU2016137524A patent/RU2016137524A/ru unknown
- 2015-02-25 JP JP2016570944A patent/JP6537532B2/ja active Active
- 2015-02-25 WO PCT/US2015/017593 patent/WO2015130838A1/en not_active Ceased
- 2015-02-25 KR KR1020167026134A patent/KR20160116016A/ko not_active Withdrawn
- 2015-02-25 JP JP2016570938A patent/JP2017506672A/ja active Pending
- 2015-02-25 US US14/631,090 patent/US9828396B2/en active Active
- 2015-02-25 KR KR1020167026158A patent/KR20160116017A/ko not_active Withdrawn
- 2015-02-25 ES ES15755617T patent/ES2771950T3/es active Active
- 2015-02-25 EP EP15755617.6A patent/EP3110418B1/en active Active
- 2015-02-25 EP EP22193148.8A patent/EP4129407B1/en active Active
- 2015-02-25 US US14/631,625 patent/US9796741B2/en active Active
- 2015-02-25 AP AP2016009434A patent/AP2016009434A0/en unknown
- 2015-02-25 WO PCT/US2015/017600 patent/WO2015130845A1/en not_active Ceased
- 2015-02-25 CN CN201580010615.5A patent/CN106456605A/zh active Pending
- 2015-02-25 CA CA2940775A patent/CA2940775A1/en not_active Abandoned
- 2015-02-25 EP EP15755233.2A patent/EP3110423A4/en not_active Withdrawn
- 2015-02-25 JP JP2016570940A patent/JP6400738B2/ja active Active
- 2015-02-25 EP EP15755701.8A patent/EP3110806A4/en not_active Withdrawn
- 2015-02-25 MX MX2016011038A patent/MX2016011038A/es unknown
- 2015-02-25 RU RU2016137832A patent/RU2703995C2/ru active
- 2015-02-25 MX MX2016011037A patent/MX2016011037A/es unknown
- 2015-02-25 AU AU2015223121A patent/AU2015223121A1/en not_active Abandoned
- 2015-02-25 AP AP2016009437A patent/AP2016009437A0/en unknown
- 2015-02-25 AP AP2016009438A patent/AP2016009438A0/en unknown
- 2015-02-25 EP EP15754619.3A patent/EP3110416A4/en not_active Withdrawn
- 2015-02-25 AP AP2016009436A patent/AP2016009436A0/en unknown
- 2015-02-25 IL IL301427A patent/IL301427B2/en unknown
- 2015-02-25 EP EP15756010.3A patent/EP3110419A4/en not_active Withdrawn
- 2015-02-25 CN CN201580010604.7A patent/CN106456604B/zh active Active
- 2015-02-25 JP JP2016570941A patent/JP2017508788A/ja active Pending
- 2015-02-25 MX MX2016011035A patent/MX373962B/es active IP Right Grant
- 2015-02-25 EA EA201691731A patent/EA201691731A1/ru unknown
- 2015-02-25 LT LTEP15755617.6T patent/LT3110418T/lt unknown
- 2015-02-25 WO PCT/US2015/017523 patent/WO2015130784A1/en not_active Ceased
- 2015-02-25 SM SM20200046T patent/SMT202000046T1/it unknown
- 2015-02-25 HU HUE15755617A patent/HUE047295T2/hu unknown
- 2015-02-25 EA EA201691728A patent/EA201691728A1/ru unknown
- 2015-02-25 CA CA2940769A patent/CA2940769A1/en not_active Abandoned
- 2015-02-25 WO PCT/US2015/017597 patent/WO2015130842A2/en not_active Ceased
- 2015-02-25 CN CN201580010598.5A patent/CN106458981B/zh active Active
- 2015-02-25 CN CN202011097580.2A patent/CN112250673A/zh active Pending
- 2015-02-25 CN CN202010351035.5A patent/CN111437278A/zh active Pending
- 2015-02-25 SI SI201531039T patent/SI3110418T1/sl unknown
- 2015-02-25 RU RU2016137678A patent/RU2016137678A/ru unknown
- 2015-02-25 CA CA2940774A patent/CA2940774A1/en not_active Abandoned
- 2015-02-25 BR BR112016019526-4A patent/BR112016019526B1/pt active IP Right Grant
- 2015-02-25 CN CN201580010603.2A patent/CN106413707A/zh active Pending
- 2015-02-25 CA CA2940645A patent/CA2940645A1/en not_active Abandoned
- 2015-02-25 WO PCT/US2015/017538 patent/WO2015130795A1/en not_active Ceased
- 2015-02-25 EA EA201691725A patent/EA035501B1/ru unknown
- 2015-02-25 CN CN201580010614.0A patent/CN106414427A/zh active Pending
- 2015-02-25 KR KR1020227010934A patent/KR20220047666A/ko not_active Ceased
- 2015-02-25 CA CA2940772A patent/CA2940772C/en active Active
- 2015-02-25 RS RS20200115A patent/RS59854B1/sr unknown
- 2015-02-25 US US14/631,233 patent/US9695205B2/en active Active
- 2015-02-25 RS RS20250190A patent/RS66541B1/sr unknown
- 2015-02-25 CN CN201580010599.XA patent/CN107073000A/zh active Pending
- 2015-02-25 US US14/631,312 patent/US9598446B2/en not_active Expired - Fee Related
- 2015-02-25 PT PT157556176T patent/PT3110418T/pt unknown
- 2015-02-25 JP JP2016570937A patent/JP2017506269A/ja active Pending
- 2015-02-25 EA EA201691730A patent/EA032690B1/ru not_active IP Right Cessation
- 2015-02-25 US US14/630,959 patent/US9643986B2/en not_active Expired - Fee Related
- 2015-02-25 KR KR1020167026171A patent/KR20160116018A/ko not_active Withdrawn
- 2015-02-25 KR KR1020167026308A patent/KR20160118368A/ko not_active Withdrawn
- 2015-02-25 MX MX2020004950A patent/MX387345B/es unknown
- 2015-02-25 WO PCT/US2015/017609 patent/WO2015130854A1/en not_active Ceased
- 2015-02-25 US US14/631,828 patent/US9758537B2/en active Active
- 2015-02-25 WO PCT/US2015/017583 patent/WO2015130830A1/en not_active Ceased
- 2015-02-25 HR HRP20250154TT patent/HRP20250154T1/hr unknown
- 2015-02-25 US US14/631,785 patent/US9663543B2/en not_active Expired - Fee Related
- 2015-02-25 EP EP19206925.0A patent/EP3623367B1/en active Active
- 2015-02-25 PL PL15755617T patent/PL3110418T3/pl unknown
- 2015-02-25 AU AU2015223132A patent/AU2015223132A1/en not_active Abandoned
- 2015-02-25 MX MX2016011034A patent/MX2016011034A/es unknown
- 2015-02-25 KR KR1020167026303A patent/KR102366025B1/ko active Active
- 2015-02-25 JP JP2016570942A patent/JP2017507184A/ja active Pending
- 2015-02-25 AU AU2015223075A patent/AU2015223075A1/en not_active Abandoned
- 2015-02-25 EP EP15755573.1A patent/EP3110805B1/en active Active
- 2015-02-25 US US14/631,683 patent/US9732104B2/en active Active
- 2015-02-25 LT LTEP22193148.8T patent/LT4129407T/lt unknown
- 2015-02-25 AU AU2015223072A patent/AU2015223072A1/en not_active Abandoned
- 2015-02-25 EP EP15754663.1A patent/EP3110417A4/en not_active Withdrawn
-
2016
- 2016-08-22 ZA ZA2016/05829A patent/ZA201605829B/en unknown
- 2016-08-22 ZA ZA2016/05832A patent/ZA201605832B/en unknown
- 2016-08-24 US US15/245,712 patent/US10005802B2/en active Active
- 2016-08-24 IL IL247453A patent/IL247453A0/en unknown
- 2016-08-24 IL IL24745016A patent/IL247450B/en active IP Right Grant
- 2016-08-24 IL IL247452A patent/IL247452B/en active IP Right Grant
- 2016-08-24 IL IL247454A patent/IL247454A0/en unknown
- 2016-08-24 US US15/246,049 patent/US20160361329A1/en not_active Abandoned
- 2016-08-24 US US15/245,788 patent/US20160362399A1/en not_active Abandoned
- 2016-08-24 US US15/245,945 patent/US20160362432A1/en not_active Abandoned
- 2016-08-24 US US15/245,872 patent/US20160362433A1/en not_active Abandoned
- 2016-08-24 IL IL247449A patent/IL247449A0/en unknown
- 2016-08-25 SA SA516371744A patent/SA516371744B1/ar unknown
-
2017
- 2017-03-20 US US15/463,701 patent/US10189869B2/en active Active
- 2017-04-24 US US15/494,926 patent/US20170226142A1/en not_active Abandoned
- 2017-05-26 US US15/607,120 patent/US10100072B2/en active Active
- 2017-06-29 US US15/638,081 patent/US10370394B2/en active Active
- 2017-06-29 US US15/638,076 patent/US10428094B2/en active Active
- 2017-08-14 US US15/676,411 patent/US10106563B2/en active Active
- 2017-09-11 US US15/700,550 patent/US10087203B2/en active Active
- 2017-09-21 US US15/711,794 patent/US10081645B2/en active Active
- 2017-11-20 US US15/818,559 patent/US20180072762A1/en not_active Abandoned
-
2018
- 2018-06-12 US US16/006,520 patent/US20180291046A1/en not_active Abandoned
- 2018-06-12 US US16/006,476 patent/US20180298043A1/en not_active Abandoned
- 2018-06-12 US US16/006,533 patent/US20180291047A1/en not_active Abandoned
- 2018-09-03 JP JP2018164274A patent/JP6688352B2/ja active Active
- 2018-09-24 US US16/140,148 patent/US10253053B2/en active Active
- 2018-10-01 US US16/148,622 patent/US10428095B2/en active Active
- 2018-10-16 US US16/162,162 patent/US10301336B2/en active Active
- 2018-10-18 US US16/164,632 patent/US10550140B2/en active Active
-
2019
- 2019-01-14 US US16/246,832 patent/US10689409B2/en active Active
- 2019-02-14 US US16/276,139 patent/US10464956B2/en active Active
- 2019-10-03 IL IL269806A patent/IL269806B/en unknown
- 2019-11-01 US US16/672,114 patent/US12065459B2/en active Active
-
2020
- 2020-01-31 CY CY20201100084T patent/CY1122550T1/el unknown
- 2020-03-30 JP JP2020060825A patent/JP6948426B2/ja active Active
- 2020-10-28 AU AU2020260434A patent/AU2020260434B2/en active Active
-
2021
- 2021-07-25 IL IL285114A patent/IL285114B2/en unknown
- 2021-09-15 JP JP2021150181A patent/JP7374967B2/ja active Active
-
2024
- 2024-08-06 NL NL301286C patent/NL301286I2/nl unknown
- 2024-08-14 FR FR24C1034C patent/FR24C1034I2/fr active Active
- 2024-08-15 HU HUS2400030C patent/HUS2400030I1/hu unknown
- 2024-08-16 FI FIC20240030C patent/FIC20240030I1/fi unknown
-
2025
- 2025-04-08 LT LTPA2025514C patent/LTPA2025514I1/lt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508789A5 (enExample) | ||
| JP2017511815A5 (enExample) | ||
| JP2018526367A5 (enExample) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| RU2016143333A (ru) | Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение | |
| JP2016515560A5 (enExample) | ||
| RU2016137832A (ru) | Соединения для лечения опосредованных комплементом нарушений | |
| JP2019522055A5 (enExample) | ||
| JP2018520195A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| RU2018134948A (ru) | Бициклические арильные монобактамовые соединения и способы их применения для лечения бактериальных инфекций | |
| JP2014501766A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2017537949A5 (enExample) | ||
| JP2016518434A5 (enExample) | ||
| RU2019100164A (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| JP2016518437A5 (enExample) | ||
| RU2016137181A (ru) | Противофиброзные пиридиноны | |
| JP2016537382A5 (enExample) | ||
| JP2014518882A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| RU2015106434A (ru) | Производные типа азаиндазола или диазаиндазола для лечения боли |